Regenerative Medical Technology (RMTG) EV to EBIT (2018 - 2026)

Regenerative Medical Technology has reported EV to EBIT for 9 years, with the latest figure at 1.12 in Q2 2026.

• On a quarterly basis, EV to EBIT fell 125.27% year-over-year to 1.12 in Q2 2026; TTM through Jun 2026 was 14.55, a 272.95% decrease from a year earlier, with the FY2025 full-year figure at 0.35, up 103.55% from the prior year.
• EV to EBIT was 1.12 for Q2 2026 at Regenerative Medical Technology, up from 2.9 in the prior quarter.
• The five-year high for EV to EBIT was 18.7 in Q1 2023, with the low at 23.43 in Q3 2024.
• Average EV to EBIT over 5 years is 1.39, with a median of 0.98 recorded in 2025.
• The largest YoY upside for EV to EBIT was 711.39% in 2025 against a maximum downside of 928.51% in 2025.
• Over 5 years, EV to EBIT stood at 0.57 in 2022, then soared by 428.27% to 3.0 in 2023, then plunged by 169.11% to 2.07 in 2024, then soared by 147.18% to 0.98 in 2025, then slumped by 214.87% to 1.12 in 2026.
• The last three EV to EBIT figures came in at 1.12 (Q2 2026), 2.9 (Q1 2026), and 0.98 (Q4 2025), per Business Quant data.